Meet Our Specialists

Dr. Elizabeth Yang is a pediatric hematologist and oncologist at Pediatric Specialists of Virginia’s (PSV) Center for Cancer and Blood Disorders (CCBD), specializing in sickle cell disease, hemoglobinopathies, thrombosis, and other hematological conditions. She is fluent in both English and Chinese. Dr. Yang earned her medical degree from Stanford University School of Medicine and completed her fellowship at St. Louis Children’s Hospital/Washington University School of Medicine. She also holds a PhD and has conducted post-doctoral research at Washington University School of Medicine.

Board certified in pediatrics, Dr. Yang has contributed to several key publications in the field of pediatric hematology, including research on sickle cell disease and hematologic conditions in pediatric populations. She has received recognition as a Top Doctor by Arlington Magazine and Washingtonian.

Dr. Yang practices at PSV’s Ashburn and Fairfax CCBD locations and is known for her compassionate care and thorough communication with patients and families. She is dedicated to educating families and involving them in the decision-making process regarding care plans.

Publications:

Phan V, Park JA, Dulman R, Lewis A, Briere N, Notarangelo B, Yang, E. Ten-year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program. Eur J Haematol. 2022;1‐9. doi:10.1111/ejh.13827. Epub 2022 July 10

Smith WR, McClish D, Lottenberg R, Sisler I, Sop D, Johnson S, Villella A, Liles D, Yang E, Chen I. A randomized controlled provider-blinded trial of community health workers in sickle cell anaemia: effects on haematologic variables and hydroxyurea adherence. Br J Haematol. 2022 Jan;196(1):193-203. doi: 10.1111/bjh.17952. Epub 2021 Nov 16

Thomas R, Wong W, Saadon R, Vilboux T, Deeken J, Niederhuber J, Hourigan S, Yang E. Gut microbial composition difference between pediatric ALL survivors and sibling. Pediatric Hematol & Oncol, 2020 May 19:1-14. doi: 10.1080/08880018.2020.1759740. PMID: 32427521

Thomas R, Dulman R, Lewis A, Notarangelo B, Yang E. Prospective Longitudinal Follow-up of Children with Sickle Cell Disease Treated with Hydroxyurea Since Infancy. Pediatr Blood Cancer. 2019 Jun 3:e27816. doi: 10.1002/pbc.27816. PMID:31157521

Yang E, Seo-Mayer P, Lezon-Geyda K, Badior KE, Li J, Casey JR, Reithmeier RAF, Gallagher PG. A Ser725Arg Mutation in Band 3 Abolishes Transport Function and Leads to Anemia and Renal Tubular Acidosis. Blood. 2018 Apr 12;131(15):1759-1763. doi: 10.1182/blood-2018-01-827725. PMID: 29483102

Levitt RN, Gourri E, Gassner C, Banez-Sese G, Salam A, Denomme GA, Yang E. Molecular Characterization and Multidisciplinary Management of Gerbich Hemolytic Disease of the Newborn. Pediatr Blood Cancer. 2018 Jun;65(6):e27014. doi: 10.1002/pbc.27014, PMID:29469208

Yang E, Voelkel EB, Lezon-Geyda K, Schulz VP, Gallagher PG: Hemoglobin C trait accentuates erythrocyte dehydration in hereditary xerocytosis. Pediatric Blood and Cancer, 2017 Aug;64(8). PMID: 28121068

Nguyen G-K, Lewis A, Goldener C, Reed B, Dulman RY, Yang E: Discontinuation of Folic Acid Supplementation in Young Patients with Sickle Cell Anemia. J Pediatr Hematol Oncol. 2017 Aug;39(6):470-472. PMID: 27571128

Maheshwari S, Kassim A, Yeh RF, Domm J, Calder C, Evans M, Manes B, Bruice K, Brown V, Ho R, Frangoul H, Yang E: Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/ml in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. Bone Marrow Transplant, 2014 Mar;49(3):366-9. PMID: 24317124